Published in Anal Biochem on January 23, 2006
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J Biol Chem (2010) 0.95
Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series. J Med Chem (2013) 0.94
Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. Bioorg Med Chem Lett (2011) 0.87
Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol (2013) 0.86
Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. Bioorg Med Chem (2008) 0.85
Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proc Natl Acad Sci U S A (2011) 0.83
Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors. J Mol Model (2012) 0.81
Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro. PLoS One (2012) 0.80
Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. PLoS One (2012) 0.80
The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells. J Biol Chem (2014) 0.77
Disruption of Heat Shock Protein 90 (Hsp90)-Protein Kinase Cδ (PKCδ) Interaction by (-)-Maackiain Suppresses Histamine H1 Receptor Gene Transcription in HeLa Cells. J Biol Chem (2015) 0.76
Synthesis and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl)phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in vitro assay. Bioorg Med Chem Lett (2008) 0.75
Cancer and virus leads by HTS, chemical design and SEA data mining. Curr Top Med Chem (2009) 0.75
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ (1993) 14.37
The genome sequence of Schizosaccharomyces pombe. Nature (2002) 14.26
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
BioJava: an open-source framework for bioinformatics. Bioinformatics (2008) 6.17
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother (1986) 4.51
Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Network. Pediatrics (1991) 4.02
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses (1993) 3.80
Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol (1993) 3.42
Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. BMJ (2001) 3.38
Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill (2009) 3.30
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst (1999) 3.07
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer (2005) 2.85
Anti-lymphocytic antibody--a review. Clin Exp Immunol (1967) 2.75
Tired, weak, or in need of rest: fatigue among general practice attenders. BMJ (1990) 2.70
Criterion validity and reliability of the SF-36 in a population sample. Qual Life Res (1994) 2.68
Safety of home delivery compared with hospital delivery in The Eastern Region Health Authority in Ireland in the years 1999-2002. Ir Med J (2003) 2.66
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Evaluation of acute physiology and chronic health evaluation III predictions of hospital mortality in an independent database. Crit Care Med (1998) 2.44
BCG immunotherapy of bladder cancer: 20 years on. Lancet (1999) 2.38
Portability issues for a structured clinical vocabulary: mapping from Yale to the Columbia medical entities dictionary. J Am Med Inform Assoc (1996) 2.24
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
Human monoclonal antibody production. Current status and future prospects. J Immunol Methods (1987) 2.21
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst (1996) 2.20
Electric fish measure distance in the dark. Nature (1998) 2.11
A randomized controlled trial of nursing home and long-stay geriatric ward care for elderly people. Age Ageing (1991) 2.11
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Laboratory staff qualifications and accuracy of proficiency test results. A national study. Arch Pathol Lab Med (1992) 2.07
Clinico-pathological findings in non-immune hydrops fetalis. Ir Med J (1991) 2.05
Lessons learned from a pilot implementation of the UMLS information sources map. J Am Med Inform Assoc (1995) 2.05
The natural history of Peyronie's disease. J Urol (1990) 2.02
Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Mult Scler (2006) 1.95
Synaptic plasticity in a cerebellum-like structure depends on temporal order. Nature (1997) 1.94
Telephone assessment of illness by practicing pediatricians. J Pediatr (1976) 1.93
Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature (1967) 1.89
Biosynthesis of the pigments of life: formation of the macrocycle. Nature (1980) 1.86
Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res (2001) 1.86
Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys (1994) 1.84
Ten years portal hypertensive surgery at Emory. Results and new perspectives. Ann Surg (1982) 1.78
DT-diaphorase and cancer chemotherapy. Biochem Pharmacol (1992) 1.78
Psychotic men remanded in custody to Brixton Prison. Br J Psychiatry (1994) 1.77
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses (1995) 1.77
The pathology of frozen shoulder. J Bone Joint Surg Br (2007) 1.77
Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors. Chem Biol (2000) 1.75
Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr (1985) 1.73
Serologic diagnosis of epidemic typhus fever. Am J Epidemiol (1977) 1.73
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. Br Med J (Clin Res Ed) (1983) 1.72
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int J Gynecol Cancer (2003) 1.70
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst (1999) 1.70
Biosynthesis of porphyrins and related macrocycles. Part 10. Vitamin B12: biochemical derivation of cobyrinic acid from uroporphyrinogen III. Studies with corresponding ring c methyl heptacarboxylic prophyrinogen, and proof of seven intact methyl transfers. J Chem Soc Perkin 1 (1977) 1.69
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol (1990) 1.66
The role of the general practitioner in the community care of people with HIV infection and AIDS: a comparative study of high- and low-prevalence areas in England. Br J Gen Pract (1998) 1.65
Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res (1980) 1.64
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
Anonymous living liver donation: donor profiles and outcomes. Am J Transplant (2010) 1.60
9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer (1990) 1.59
A genomewide suppressor and enhancer analysis of cdc13-1 reveals varied cellular processes influencing telomere capping in Saccharomyces cerevisiae. Genetics (2008) 1.58
Primary pulmonary hypertension between inflammation and cancer. Chest (1998) 1.57
How reliable are SIDS rates? Arch Dis Child (2005) 1.57
Occurrence of Cryptosporidium oocysts in fecal samples submitted for routine microbiological examination. J Clin Microbiol (1985) 1.57
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
Some factors influencing the ability of anti-lymphocytic antibody to suppress humoral antibody formation. Clin Exp Immunol (1967) 1.52
Minimizing errors of omission: behavioural reenforcement of heparin to avert venous emboli: the BEHAVE study. Crit Care Med (2006) 1.52
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol (2002) 1.50
In vitro translation of the Two RNAs of Nodamura virus, a novel mammalian virus with a divided genome. J Virol (1978) 1.49
The preparation and properties of anti-lymphocytic sera. Prog Surg (1969) 1.48
Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis. Intensive Care Med (2013) 1.46
Developmental issues in child health psychology. Am Psychol (1986) 1.46
Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses (1994) 1.45
[Surgical treatment of the single non traumatic perforation of small bowel: excision-suture or resection-anastomosis]. Ann Chir (2005) 1.45
Routine day-case laparoscopic cholecystectomy. Br J Surg (2004) 1.45
Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem (2011) 1.44
Antibody raised against soluble CD4-rgp120 complex recognizes the CD4 moiety and blocks membrane fusion without inhibiting CD4-gp120 binding. J Exp Med (1990) 1.44
Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol (2000) 1.43
Structure-property correlations in a combinatorial library of degradable biomaterials. J Biomed Mater Res (1998) 1.42
Atomic-scale visualization of inertial dynamics. Science (2005) 1.42
Site-specific recombination and circular chromosome segregation. Philos Trans R Soc Lond B Biol Sci (1995) 1.42
Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours. Br J Cancer (1979) 1.42
Continuous thoracic epidural analgesia versus combined spinal/thoracic epidural analgesia on pain, pulmonary function and the metabolic response following colonic resection. Acta Anaesthesiol Scand (1996) 1.42
Effect of antilymphocytic antibody and antibody fragments on skin-homograft survival and the blood-lymphocyte count in rats. Lancet (1967) 1.41
Oral acyclovir for chickenpox. Cutis (1991) 1.40
Effect of anti-rat lymphocyte antibody on humoral antibody formation. Nature (1967) 1.40
Fertility desires and fertility: hers, his, and theirs. Demography (1990) 1.40
Carcinoma of the colon associated with systemic sclerosis. N Y State J Med (1990) 1.39
Comparison of two proximal osteotomies for the treatment of hallux valgus. Foot Ankle Int (1998) 1.39
Evaluation of children's sexual behaviors and incorporation of base rates in judgments of sexual abuse. Child Abuse Negl (1995) 1.38
Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol (1992) 1.38
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia (2011) 1.36
Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J Virol (1989) 1.36
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35